At a glance
ClinicalIndex Comparison RecordN/ACompleted· 175 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exosome-Based Liquid Biopsy Assay to Detect Molecular Residual Disease for the Identification of High-Risk Patients With Stage II-III Colorectal Cancer
In Brief
An observational study for Colo-rectal Cancer and Colorectal Cancer Recurrent. Completed, enrolled 175 participants across 1 site.
Detailed Summary
This study aims to establish an exosome-based liquid biopsy signature to detect molecular residual disease (MRD) in stage II-III colorectal cancer (CRC) patients. Identifying patients with MRD after surgery is crucial for selecting appropriate candidates for adjuvant chemotherapy (ACT), allowing for more personalized treatment approaches and potentially improving patient outcomes.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsColo-rectal Cancer, Colorectal Cancer Recurrent
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202420252026
Enrollment StartApr 2023
First PostedOct 2024
Primary CompletionJan 2026
Study CompletionFeb 2026
TodayJul 2026
First PostedOct 23, 2024
Enrollment StartApr 1, 2023
Primary CompletionJan 18, 2026
Study CompletionFeb 18, 2026
TodayJul 1, 2026
Enrollment to primary: 2.8 yearsPosted 1.7 years ago